Use of approved Lu‐177 radiopharmaceuticals in patients with end‐stage renal disease: A review of the literature and proposed treatment algorithm
Peptide receptor radionuclide therapy (PRRT) can be a very useful treatment for patients with neuroendocrine neoplasms and metastatic castration-resistant prostate cancer but it is routinely avoided …